XSDR:LSE:LSE-Xtrackers MSCI Europe Health Care ESG Screened UCITS ETF 1C (GBX)

ETF | Others |

Last Closing

USD 20125

Change

+155.00 (+0.78)%

Market Cap

USD 0.15B

Volume

96.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-23 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

N/A

USD 292,109.69B
XMTD:LSE Xtrackers MSCI Taiwan UCITS ET..

N/A

USD 292,109.19B
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

N/A

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

N/A

USD 592.18B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 592.18B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

N/A

USD 331.07B
0QZK:LSE Coca-Cola Co.

N/A

USD 266.08B
0QZO:LSE 0QZO

N/A

USD 258.54B

ETFs Containing XSDR:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.87% 88% B+ 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.87% 88% B+ 78% C+
Trailing 12 Months  
Capital Gain 12.95% 53% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.95% 52% F 58% F
Trailing 5 Years  
Capital Gain 66.03% 75% C 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.03% 73% C 77% C+
Average Annual (5 Year Horizon)  
Capital Gain 8.11% 65% D 68% D+
Dividend Return 8.11% 64% D 67% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 6.32% 81% B- 90% A-
Risk Adjusted Return 128.27% 100% F 100% F
Market Capitalization 0.15B 51% F 44% F

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike